Este Sitio Web utiliza cookies propias y de terceros para mejorar nuestros servicios y analizar los hábitos de navegación del usuario.
Si continúas navegando, consideramos que aceptas su uso. Puedes ampliar esta información visitando nuestra Política de cookies.
Chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives, and 50% of them endure inadequate pain relief for at least two years. (Breivik H, et al. 2005).
It is estimated that 9% of the U.S. adult population suffer from moderate to severe non-cancer related chronic pain. (American Pain Society).
Chronic pain is characterized by high levels of unmet medical needs. Current treatments do not provide satisfactory levels of pain relief in the majority of patients and are associated with high levels of not desirable events.
Chronic pain is a major public health problem with a profound impact on the quality of life of the patient (sleeping disorders, reduced mobility or depression) affecting work productivity and with a high impact in the cost of healthcare.
The treatment of pain is one of our main priorities. See video to learn more about our projects in pain.
A rare disease occurs in less than 200,000 individuals in the United States, or less than 5 per 10,000 individuals in the European Union. However the number of sufferers may still be high, as there are some 7,000 known rare diseases.
Diagnosis of many rare diseases are lengthy and time consuming and is only initiated once the symptoms have begun to appear like the Sanfilippo Syndrome, a lysosomal storage disease caused by the loss of the activity of the enzyme sulfamidase.
Sanfilippo Syndrome is a devastating disease that leads to progressive and significant deterioration in mental status of children who rarely live beyond their twenties.
Gene therapy approach to treat Sanfilippo Syndrome, a devastating rare disease affecting children. See video to learn more about our research efforts in rare diseases.